nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Fingolimod—multiple sclerosis	0.0693	0.246	CbGbCtD
Lurasidone—HTR2A—trigeminal nucleus—multiple sclerosis	0.051	0.231	CbGeAlD
Lurasidone—CYP3A4—Methylprednisolone—multiple sclerosis	0.0447	0.158	CbGbCtD
Lurasidone—CYP3A4—Triamcinolone—multiple sclerosis	0.0338	0.12	CbGbCtD
Lurasidone—CYP3A4—Mitoxantrone—multiple sclerosis	0.0326	0.116	CbGbCtD
Lurasidone—CYP3A4—Betamethasone—multiple sclerosis	0.029	0.103	CbGbCtD
Lurasidone—CYP3A4—Prednisolone—multiple sclerosis	0.0287	0.102	CbGbCtD
Lurasidone—CYP3A4—Prednisone—multiple sclerosis	0.0271	0.0959	CbGbCtD
Lurasidone—CYP3A4—Dexamethasone—multiple sclerosis	0.0169	0.0599	CbGbCtD
Lurasidone—HTR7—pons—multiple sclerosis	0.0151	0.0684	CbGeAlD
Lurasidone—HTR2A—trigeminal nerve—multiple sclerosis	0.0134	0.0606	CbGeAlD
Lurasidone—HTR7—peripheral nervous system—multiple sclerosis	0.0101	0.0455	CbGeAlD
Lurasidone—HTR2A—pons—multiple sclerosis	0.00944	0.0427	CbGeAlD
Lurasidone—HTR7—nerve—multiple sclerosis	0.00785	0.0355	CbGeAlD
Lurasidone—DRD2—nerve—multiple sclerosis	0.00742	0.0336	CbGeAlD
Lurasidone—ADRA2A—peripheral nervous system—multiple sclerosis	0.00738	0.0334	CbGeAlD
Lurasidone—HTR2A—pineal body—multiple sclerosis	0.00674	0.0305	CbGeAlD
Lurasidone—HTR2A—peripheral nervous system—multiple sclerosis	0.00628	0.0284	CbGeAlD
Lurasidone—HTR2A—nerve—multiple sclerosis	0.00489	0.0221	CbGeAlD
Lurasidone—HTR1A—brainstem—multiple sclerosis	0.00353	0.0159	CbGeAlD
Lurasidone—HTR7—brainstem—multiple sclerosis	0.00337	0.0152	CbGeAlD
Lurasidone—DRD2—brainstem—multiple sclerosis	0.00319	0.0144	CbGeAlD
Lurasidone—DRD2—retina—multiple sclerosis	0.00307	0.0139	CbGeAlD
Lurasidone—HTR7—medulla oblongata—multiple sclerosis	0.00235	0.0106	CbGeAlD
Lurasidone—HTR1A—midbrain—multiple sclerosis	0.00225	0.0102	CbGeAlD
Lurasidone—HTR1A—spinal cord—multiple sclerosis	0.00219	0.00992	CbGeAlD
Lurasidone—ADRA2C—medulla oblongata—multiple sclerosis	0.00216	0.00977	CbGeAlD
Lurasidone—HTR7—midbrain—multiple sclerosis	0.00215	0.00971	CbGeAlD
Lurasidone—HTR2A—brainstem—multiple sclerosis	0.0021	0.0095	CbGeAlD
Lurasidone—HTR7—spinal cord—multiple sclerosis	0.0021	0.00948	CbGeAlD
Lurasidone—DRD2—midbrain—multiple sclerosis	0.00203	0.00918	CbGeAlD
Lurasidone—HTR2A—retina—multiple sclerosis	0.00203	0.00917	CbGeAlD
Lurasidone—ADRA2C—midbrain—multiple sclerosis	0.00197	0.00893	CbGeAlD
Lurasidone—ADRA2C—spinal cord—multiple sclerosis	0.00193	0.00871	CbGeAlD
Lurasidone—HTR1A—nervous system—multiple sclerosis	0.00185	0.00835	CbGeAlD
Lurasidone—HTR1A—central nervous system—multiple sclerosis	0.00178	0.00804	CbGeAlD
Lurasidone—HTR7—nervous system—multiple sclerosis	0.00177	0.00798	CbGeAlD
Lurasidone—HTR1A—cerebellum—multiple sclerosis	0.00174	0.00786	CbGeAlD
Lurasidone—ADRA2A—medulla oblongata—multiple sclerosis	0.00172	0.00779	CbGeAlD
Lurasidone—HTR7—central nervous system—multiple sclerosis	0.0017	0.00769	CbGeAlD
Lurasidone—DRD2—nervous system—multiple sclerosis	0.00167	0.00755	CbGeAlD
Lurasidone—HTR7—cerebellum—multiple sclerosis	0.00166	0.00751	CbGeAlD
Lurasidone—ADRA2C—nervous system—multiple sclerosis	0.00162	0.00734	CbGeAlD
Lurasidone—DRD2—central nervous system—multiple sclerosis	0.00161	0.00727	CbGeAlD
Lurasidone—ADRA2A—midbrain—multiple sclerosis	0.00157	0.00712	CbGeAlD
Lurasidone—DRD2—cerebellum—multiple sclerosis	0.00157	0.0071	CbGeAlD
Lurasidone—ADRA2C—central nervous system—multiple sclerosis	0.00156	0.00707	CbGeAlD
Lurasidone—ADRA2A—spinal cord—multiple sclerosis	0.00154	0.00695	CbGeAlD
Lurasidone—ADRA2C—cerebellum—multiple sclerosis	0.00153	0.00691	CbGeAlD
Lurasidone—HTR2A—medulla oblongata—multiple sclerosis	0.00147	0.00663	CbGeAlD
Lurasidone—HTR1A—brain—multiple sclerosis	0.00141	0.00639	CbGeAlD
Lurasidone—HTR7—brain—multiple sclerosis	0.00135	0.0061	CbGeAlD
Lurasidone—HTR2A—midbrain—multiple sclerosis	0.00134	0.00606	CbGeAlD
Lurasidone—HTR2A—spinal cord—multiple sclerosis	0.00131	0.00591	CbGeAlD
Lurasidone—ADRA2A—nervous system—multiple sclerosis	0.00129	0.00586	CbGeAlD
Lurasidone—DRD2—brain—multiple sclerosis	0.00128	0.00577	CbGeAlD
Lurasidone—ADRA2A—central nervous system—multiple sclerosis	0.00125	0.00564	CbGeAlD
Lurasidone—ADRA2C—brain—multiple sclerosis	0.00124	0.00561	CbGeAlD
Lurasidone—ADRA2A—cerebellum—multiple sclerosis	0.00122	0.00551	CbGeAlD
Lurasidone—HTR2A—nervous system—multiple sclerosis	0.0011	0.00498	CbGeAlD
Lurasidone—HTR2A—central nervous system—multiple sclerosis	0.00106	0.00479	CbGeAlD
Lurasidone—HTR2A—cerebellum—multiple sclerosis	0.00104	0.00469	CbGeAlD
Lurasidone—CYP3A4—nervous system—multiple sclerosis	0.00102	0.00461	CbGeAlD
Lurasidone—ADRA2A—brain—multiple sclerosis	0.00099	0.00448	CbGeAlD
Lurasidone—CYP3A4—central nervous system—multiple sclerosis	0.000981	0.00444	CbGeAlD
Lurasidone—HTR2A—brain—multiple sclerosis	0.000841	0.00381	CbGeAlD
Lurasidone—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000599	0.00157	CcSEcCtD
Lurasidone—Malaise—Prednisolone—multiple sclerosis	0.000596	0.00156	CcSEcCtD
Lurasidone—Nausea—Cladribine—multiple sclerosis	0.000594	0.00156	CcSEcCtD
Lurasidone—Vertigo—Prednisolone—multiple sclerosis	0.000594	0.00156	CcSEcCtD
Lurasidone—Syncope—Prednisolone—multiple sclerosis	0.000593	0.00155	CcSEcCtD
Lurasidone—Eye disorder—Betamethasone—multiple sclerosis	0.000592	0.00155	CcSEcCtD
Lurasidone—Eye disorder—Dexamethasone—multiple sclerosis	0.000592	0.00155	CcSEcCtD
Lurasidone—Back pain—Triamcinolone—multiple sclerosis	0.000588	0.00154	CcSEcCtD
Lurasidone—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000586	0.00154	CcSEcCtD
Lurasidone—Somnolence—Mitoxantrone—multiple sclerosis	0.000585	0.00153	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisolone—multiple sclerosis	0.000581	0.00152	CcSEcCtD
Lurasidone—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000579	0.00152	CcSEcCtD
Lurasidone—Angiopathy—Betamethasone—multiple sclerosis	0.000575	0.00151	CcSEcCtD
Lurasidone—Angiopathy—Dexamethasone—multiple sclerosis	0.000575	0.00151	CcSEcCtD
Lurasidone—Convulsion—Prednisolone—multiple sclerosis	0.000573	0.0015	CcSEcCtD
Lurasidone—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000572	0.0015	CcSEcCtD
Lurasidone—Hypertension—Prednisolone—multiple sclerosis	0.000571	0.0015	CcSEcCtD
Lurasidone—Eosinophilia—Methotrexate—multiple sclerosis	0.00057	0.00149	CcSEcCtD
Lurasidone—Fatigue—Mitoxantrone—multiple sclerosis	0.000567	0.00149	CcSEcCtD
Lurasidone—Arrhythmia—Dexamethasone—multiple sclerosis	0.000566	0.00148	CcSEcCtD
Lurasidone—Arrhythmia—Betamethasone—multiple sclerosis	0.000566	0.00148	CcSEcCtD
Lurasidone—Bradycardia—Prednisone—multiple sclerosis	0.000562	0.00147	CcSEcCtD
Lurasidone—Diarrhoea—Azathioprine—multiple sclerosis	0.000556	0.00146	CcSEcCtD
Lurasidone—Angioedema—Triamcinolone—multiple sclerosis	0.000555	0.00146	CcSEcCtD
Lurasidone—Angioedema—Methylprednisolone—multiple sclerosis	0.000554	0.00145	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000552	0.00145	CcSEcCtD
Lurasidone—Malaise—Triamcinolone—multiple sclerosis	0.000548	0.00144	CcSEcCtD
Lurasidone—Malaise—Methylprednisolone—multiple sclerosis	0.000547	0.00143	CcSEcCtD
Lurasidone—Vertigo—Triamcinolone—multiple sclerosis	0.000546	0.00143	CcSEcCtD
Lurasidone—Syncope—Triamcinolone—multiple sclerosis	0.000545	0.00143	CcSEcCtD
Lurasidone—Vertigo—Methylprednisolone—multiple sclerosis	0.000545	0.00143	CcSEcCtD
Lurasidone—Syncope—Methylprednisolone—multiple sclerosis	0.000544	0.00142	CcSEcCtD
Lurasidone—Connective tissue disorder—Prednisone—multiple sclerosis	0.000542	0.00142	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—multiple sclerosis	0.000539	0.00141	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—multiple sclerosis	0.000539	0.00141	CcSEcCtD
Lurasidone—Dizziness—Azathioprine—multiple sclerosis	0.000538	0.00141	CcSEcCtD
Lurasidone—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000538	0.00141	CcSEcCtD
Lurasidone—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000534	0.0014	CcSEcCtD
Lurasidone—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000533	0.0014	CcSEcCtD
Lurasidone—Shock—Prednisolone—multiple sclerosis	0.000531	0.00139	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000531	0.00139	CcSEcCtD
Lurasidone—Convulsion—Triamcinolone—multiple sclerosis	0.000527	0.00138	CcSEcCtD
Lurasidone—Tachycardia—Prednisolone—multiple sclerosis	0.000526	0.00138	CcSEcCtD
Lurasidone—Convulsion—Methylprednisolone—multiple sclerosis	0.000525	0.00138	CcSEcCtD
Lurasidone—Hypertension—Triamcinolone—multiple sclerosis	0.000525	0.00137	CcSEcCtD
Lurasidone—Hypertension—Methylprednisolone—multiple sclerosis	0.000524	0.00137	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000521	0.00137	CcSEcCtD
Lurasidone—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00052	0.00136	CcSEcCtD
Lurasidone—Myalgia—Triamcinolone—multiple sclerosis	0.000517	0.00136	CcSEcCtD
Lurasidone—Vomiting—Azathioprine—multiple sclerosis	0.000517	0.00135	CcSEcCtD
Lurasidone—Myalgia—Methylprednisolone—multiple sclerosis	0.000516	0.00135	CcSEcCtD
Lurasidone—Eye disorder—Prednisone—multiple sclerosis	0.000516	0.00135	CcSEcCtD
Lurasidone—Anxiety—Methylprednisolone—multiple sclerosis	0.000515	0.00135	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—multiple sclerosis	0.000514	0.00135	CcSEcCtD
Lurasidone—Infestation—Methotrexate—multiple sclerosis	0.000514	0.00135	CcSEcCtD
Lurasidone—Rash—Azathioprine—multiple sclerosis	0.000513	0.00134	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000513	0.00134	CcSEcCtD
Lurasidone—Dermatitis—Azathioprine—multiple sclerosis	0.000512	0.00134	CcSEcCtD
Lurasidone—Dry mouth—Triamcinolone—multiple sclerosis	0.000506	0.00133	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—multiple sclerosis	0.000505	0.00132	CcSEcCtD
Lurasidone—Angioedema—Dexamethasone—multiple sclerosis	0.000504	0.00132	CcSEcCtD
Lurasidone—Angioedema—Betamethasone—multiple sclerosis	0.000504	0.00132	CcSEcCtD
Lurasidone—Angiopathy—Prednisone—multiple sclerosis	0.000501	0.00131	CcSEcCtD
Lurasidone—Malaise—Betamethasone—multiple sclerosis	0.000497	0.0013	CcSEcCtD
Lurasidone—Malaise—Dexamethasone—multiple sclerosis	0.000497	0.0013	CcSEcCtD
Lurasidone—Vertigo—Betamethasone—multiple sclerosis	0.000495	0.0013	CcSEcCtD
Lurasidone—Vertigo—Dexamethasone—multiple sclerosis	0.000495	0.0013	CcSEcCtD
Lurasidone—Syncope—Betamethasone—multiple sclerosis	0.000495	0.0013	CcSEcCtD
Lurasidone—Syncope—Dexamethasone—multiple sclerosis	0.000495	0.0013	CcSEcCtD
Lurasidone—Arrhythmia—Prednisone—multiple sclerosis	0.000493	0.00129	CcSEcCtD
Lurasidone—Infection—Triamcinolone—multiple sclerosis	0.000493	0.00129	CcSEcCtD
Lurasidone—Infection—Methylprednisolone—multiple sclerosis	0.000492	0.00129	CcSEcCtD
Lurasidone—Shock—Triamcinolone—multiple sclerosis	0.000488	0.00128	CcSEcCtD
Lurasidone—Insomnia—Prednisolone—multiple sclerosis	0.000488	0.00128	CcSEcCtD
Lurasidone—Shock—Methylprednisolone—multiple sclerosis	0.000487	0.00128	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000486	0.00127	CcSEcCtD
Lurasidone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000485	0.00127	CcSEcCtD
Lurasidone—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000485	0.00127	CcSEcCtD
Lurasidone—Loss of consciousness—Betamethasone—multiple sclerosis	0.000485	0.00127	CcSEcCtD
Lurasidone—Tachycardia—Triamcinolone—multiple sclerosis	0.000484	0.00127	CcSEcCtD
Lurasidone—Mental disorder—Prednisone—multiple sclerosis	0.000483	0.00127	CcSEcCtD
Lurasidone—Nausea—Azathioprine—multiple sclerosis	0.000483	0.00127	CcSEcCtD
Lurasidone—Tachycardia—Methylprednisolone—multiple sclerosis	0.000483	0.00127	CcSEcCtD
Lurasidone—Skin disorder—Methylprednisolone—multiple sclerosis	0.000481	0.00126	CcSEcCtD
Lurasidone—Malnutrition—Prednisone—multiple sclerosis	0.00048	0.00126	CcSEcCtD
Lurasidone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00048	0.00126	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—multiple sclerosis	0.000479	0.00126	CcSEcCtD
Lurasidone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000478	0.00125	CcSEcCtD
Lurasidone—Convulsion—Betamethasone—multiple sclerosis	0.000478	0.00125	CcSEcCtD
Lurasidone—Convulsion—Dexamethasone—multiple sclerosis	0.000478	0.00125	CcSEcCtD
Lurasidone—Hypertension—Dexamethasone—multiple sclerosis	0.000476	0.00125	CcSEcCtD
Lurasidone—Hypertension—Betamethasone—multiple sclerosis	0.000476	0.00125	CcSEcCtD
Lurasidone—Asthenia—Mitoxantrone—multiple sclerosis	0.000472	0.00124	CcSEcCtD
Lurasidone—Myalgia—Betamethasone—multiple sclerosis	0.00047	0.00123	CcSEcCtD
Lurasidone—Myalgia—Dexamethasone—multiple sclerosis	0.00047	0.00123	CcSEcCtD
Lurasidone—Anxiety—Dexamethasone—multiple sclerosis	0.000468	0.00123	CcSEcCtD
Lurasidone—Anxiety—Betamethasone—multiple sclerosis	0.000468	0.00123	CcSEcCtD
Lurasidone—Hypotension—Methylprednisolone—multiple sclerosis	0.000462	0.00121	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000455	0.00119	CcSEcCtD
Lurasidone—Vision blurred—Prednisone—multiple sclerosis	0.000453	0.00119	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—multiple sclerosis	0.000452	0.00118	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000452	0.00118	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000451	0.00118	CcSEcCtD
Lurasidone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00045	0.00118	CcSEcCtD
Lurasidone—Insomnia—Triamcinolone—multiple sclerosis	0.000449	0.00118	CcSEcCtD
Lurasidone—Insomnia—Methylprednisolone—multiple sclerosis	0.000448	0.00117	CcSEcCtD
Lurasidone—Infection—Betamethasone—multiple sclerosis	0.000447	0.00117	CcSEcCtD
Lurasidone—Infection—Dexamethasone—multiple sclerosis	0.000447	0.00117	CcSEcCtD
Lurasidone—Anaemia—Prednisone—multiple sclerosis	0.000444	0.00116	CcSEcCtD
Lurasidone—Shock—Dexamethasone—multiple sclerosis	0.000443	0.00116	CcSEcCtD
Lurasidone—Shock—Betamethasone—multiple sclerosis	0.000443	0.00116	CcSEcCtD
Lurasidone—Dyspnoea—Triamcinolone—multiple sclerosis	0.000442	0.00116	CcSEcCtD
Lurasidone—Nervous system disorder—Betamethasone—multiple sclerosis	0.000441	0.00116	CcSEcCtD
Lurasidone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000441	0.00116	CcSEcCtD
Lurasidone—Agitation—Prednisone—multiple sclerosis	0.000441	0.00116	CcSEcCtD
Lurasidone—Tachycardia—Betamethasone—multiple sclerosis	0.000439	0.00115	CcSEcCtD
Lurasidone—Tachycardia—Dexamethasone—multiple sclerosis	0.000439	0.00115	CcSEcCtD
Lurasidone—Angioedema—Prednisone—multiple sclerosis	0.000439	0.00115	CcSEcCtD
Lurasidone—Dyspepsia—Triamcinolone—multiple sclerosis	0.000437	0.00114	CcSEcCtD
Lurasidone—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000436	0.00114	CcSEcCtD
Lurasidone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000435	0.00114	CcSEcCtD
Lurasidone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000435	0.00114	CcSEcCtD
Lurasidone—Malaise—Prednisone—multiple sclerosis	0.000433	0.00113	CcSEcCtD
Lurasidone—Vertigo—Prednisone—multiple sclerosis	0.000432	0.00113	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—multiple sclerosis	0.000431	0.00113	CcSEcCtD
Lurasidone—Syncope—Prednisone—multiple sclerosis	0.000431	0.00113	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—multiple sclerosis	0.000428	0.00112	CcSEcCtD
Lurasidone—Fatigue—Triamcinolone—multiple sclerosis	0.000428	0.00112	CcSEcCtD
Lurasidone—Fatigue—Methylprednisolone—multiple sclerosis	0.000427	0.00112	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisone—multiple sclerosis	0.000422	0.00111	CcSEcCtD
Lurasidone—Hypotension—Dexamethasone—multiple sclerosis	0.000421	0.0011	CcSEcCtD
Lurasidone—Hypotension—Betamethasone—multiple sclerosis	0.000421	0.0011	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—multiple sclerosis	0.000418	0.0011	CcSEcCtD
Lurasidone—Vomiting—Mitoxantrone—multiple sclerosis	0.000418	0.0011	CcSEcCtD
Lurasidone—Convulsion—Prednisone—multiple sclerosis	0.000416	0.00109	CcSEcCtD
Lurasidone—Hypertension—Prednisone—multiple sclerosis	0.000415	0.00109	CcSEcCtD
Lurasidone—Rash—Mitoxantrone—multiple sclerosis	0.000415	0.00109	CcSEcCtD
Lurasidone—Dermatitis—Mitoxantrone—multiple sclerosis	0.000414	0.00109	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00041	0.00107	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00041	0.00107	CcSEcCtD
Lurasidone—Myalgia—Prednisone—multiple sclerosis	0.000409	0.00107	CcSEcCtD
Lurasidone—Anxiety—Prednisone—multiple sclerosis	0.000407	0.00107	CcSEcCtD
Lurasidone—Insomnia—Betamethasone—multiple sclerosis	0.000407	0.00107	CcSEcCtD
Lurasidone—Insomnia—Dexamethasone—multiple sclerosis	0.000407	0.00107	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000406	0.00106	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000405	0.00106	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—multiple sclerosis	0.000404	0.00106	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—multiple sclerosis	0.000401	0.00105	CcSEcCtD
Lurasidone—Dyspepsia—Betamethasone—multiple sclerosis	0.000396	0.00104	CcSEcCtD
Lurasidone—Dyspepsia—Dexamethasone—multiple sclerosis	0.000396	0.00104	CcSEcCtD
Lurasidone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000391	0.00103	CcSEcCtD
Lurasidone—Decreased appetite—Betamethasone—multiple sclerosis	0.000391	0.00103	CcSEcCtD
Lurasidone—Decreased appetite—Dexamethasone—multiple sclerosis	0.000391	0.00103	CcSEcCtD
Lurasidone—Nausea—Mitoxantrone—multiple sclerosis	0.000391	0.00102	CcSEcCtD
Lurasidone—Infection—Prednisone—multiple sclerosis	0.000389	0.00102	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000389	0.00102	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000389	0.00102	CcSEcCtD
Lurasidone—Back pain—Methotrexate—multiple sclerosis	0.000388	0.00102	CcSEcCtD
Lurasidone—Fatigue—Betamethasone—multiple sclerosis	0.000388	0.00102	CcSEcCtD
Lurasidone—Fatigue—Dexamethasone—multiple sclerosis	0.000388	0.00102	CcSEcCtD
Lurasidone—Shock—Prednisone—multiple sclerosis	0.000386	0.00101	CcSEcCtD
Lurasidone—Nervous system disorder—Prednisone—multiple sclerosis	0.000384	0.00101	CcSEcCtD
Lurasidone—Tachycardia—Prednisone—multiple sclerosis	0.000383	0.001	CcSEcCtD
Lurasidone—Skin disorder—Prednisone—multiple sclerosis	0.000381	0.000998	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisone—multiple sclerosis	0.000379	0.000993	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—multiple sclerosis	0.000378	0.000991	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—multiple sclerosis	0.000371	0.000972	CcSEcCtD
Lurasidone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000368	0.000964	CcSEcCtD
Lurasidone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000368	0.000964	CcSEcCtD
Lurasidone—Malaise—Methotrexate—multiple sclerosis	0.000362	0.000948	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—multiple sclerosis	0.000361	0.000945	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—multiple sclerosis	0.000359	0.000941	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000357	0.000936	CcSEcCtD
Lurasidone—Dizziness—Prednisolone—multiple sclerosis	0.000357	0.000935	CcSEcCtD
Lurasidone—Asthenia—Triamcinolone—multiple sclerosis	0.000356	0.000932	CcSEcCtD
Lurasidone—Abdominal pain—Dexamethasone—multiple sclerosis	0.000356	0.000932	CcSEcCtD
Lurasidone—Abdominal pain—Betamethasone—multiple sclerosis	0.000356	0.000932	CcSEcCtD
Lurasidone—Asthenia—Methylprednisolone—multiple sclerosis	0.000355	0.00093	CcSEcCtD
Lurasidone—Insomnia—Prednisone—multiple sclerosis	0.000355	0.000929	CcSEcCtD
Lurasidone—Pruritus—Triamcinolone—multiple sclerosis	0.000351	0.00092	CcSEcCtD
Lurasidone—Pruritus—Methylprednisolone—multiple sclerosis	0.00035	0.000917	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—multiple sclerosis	0.000348	0.000911	CcSEcCtD
Lurasidone—Dyspepsia—Prednisone—multiple sclerosis	0.000345	0.000904	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—multiple sclerosis	0.000342	0.000895	CcSEcCtD
Lurasidone—Decreased appetite—Prednisone—multiple sclerosis	0.000341	0.000893	CcSEcCtD
Lurasidone—Rash—Prednisolone—multiple sclerosis	0.00034	0.000891	CcSEcCtD
Lurasidone—Dermatitis—Prednisolone—multiple sclerosis	0.00034	0.00089	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000339	0.000889	CcSEcCtD
Lurasidone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000339	0.000887	CcSEcCtD
Lurasidone—Fatigue—Prednisone—multiple sclerosis	0.000338	0.000885	CcSEcCtD
Lurasidone—Dizziness—Triamcinolone—multiple sclerosis	0.000328	0.000859	CcSEcCtD
Lurasidone—Dizziness—Methylprednisolone—multiple sclerosis	0.000327	0.000858	CcSEcCtD
Lurasidone—Infection—Methotrexate—multiple sclerosis	0.000325	0.000853	CcSEcCtD
Lurasidone—Asthenia—Betamethasone—multiple sclerosis	0.000323	0.000846	CcSEcCtD
Lurasidone—Asthenia—Dexamethasone—multiple sclerosis	0.000323	0.000846	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—multiple sclerosis	0.000321	0.000842	CcSEcCtD
Lurasidone—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000321	0.00084	CcSEcCtD
Lurasidone—Nausea—Prednisolone—multiple sclerosis	0.00032	0.000839	CcSEcCtD
Lurasidone—Pruritus—Betamethasone—multiple sclerosis	0.000318	0.000834	CcSEcCtD
Lurasidone—Pruritus—Dexamethasone—multiple sclerosis	0.000318	0.000834	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—multiple sclerosis	0.000318	0.000834	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000317	0.00083	CcSEcCtD
Lurasidone—Vomiting—Triamcinolone—multiple sclerosis	0.000315	0.000826	CcSEcCtD
Lurasidone—Vomiting—Methylprednisolone—multiple sclerosis	0.000315	0.000825	CcSEcCtD
Lurasidone—Rash—Triamcinolone—multiple sclerosis	0.000313	0.000819	CcSEcCtD
Lurasidone—Dermatitis—Triamcinolone—multiple sclerosis	0.000312	0.000819	CcSEcCtD
Lurasidone—Rash—Methylprednisolone—multiple sclerosis	0.000312	0.000818	CcSEcCtD
Lurasidone—Dermatitis—Methylprednisolone—multiple sclerosis	0.000312	0.000817	CcSEcCtD
Lurasidone—Abdominal pain—Prednisone—multiple sclerosis	0.00031	0.000812	CcSEcCtD
Lurasidone—Diarrhoea—Dexamethasone—multiple sclerosis	0.000308	0.000807	CcSEcCtD
Lurasidone—Diarrhoea—Betamethasone—multiple sclerosis	0.000308	0.000807	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—multiple sclerosis	0.000306	0.000802	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000298	0.000782	CcSEcCtD
Lurasidone—Dizziness—Dexamethasone—multiple sclerosis	0.000298	0.00078	CcSEcCtD
Lurasidone—Dizziness—Betamethasone—multiple sclerosis	0.000298	0.00078	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—multiple sclerosis	0.000296	0.000776	CcSEcCtD
Lurasidone—Nausea—Triamcinolone—multiple sclerosis	0.000295	0.000772	CcSEcCtD
Lurasidone—Nausea—Methylprednisolone—multiple sclerosis	0.000294	0.00077	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—multiple sclerosis	0.000292	0.000765	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—multiple sclerosis	0.000291	0.000763	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—multiple sclerosis	0.000288	0.000756	CcSEcCtD
Lurasidone—Vomiting—Dexamethasone—multiple sclerosis	0.000286	0.00075	CcSEcCtD
Lurasidone—Vomiting—Betamethasone—multiple sclerosis	0.000286	0.00075	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—multiple sclerosis	0.000285	0.000746	CcSEcCtD
Lurasidone—Rash—Dexamethasone—multiple sclerosis	0.000284	0.000744	CcSEcCtD
Lurasidone—Rash—Betamethasone—multiple sclerosis	0.000284	0.000744	CcSEcCtD
Lurasidone—Dermatitis—Dexamethasone—multiple sclerosis	0.000284	0.000743	CcSEcCtD
Lurasidone—Dermatitis—Betamethasone—multiple sclerosis	0.000284	0.000743	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000283	0.000741	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—multiple sclerosis	0.000282	0.00074	CcSEcCtD
Lurasidone—Asthenia—Prednisone—multiple sclerosis	0.000281	0.000737	CcSEcCtD
Lurasidone—Pruritus—Prednisone—multiple sclerosis	0.000277	0.000727	CcSEcCtD
Lurasidone—Diarrhoea—Prednisone—multiple sclerosis	0.000268	0.000703	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000268	0.000702	CcSEcCtD
Lurasidone—Nausea—Dexamethasone—multiple sclerosis	0.000267	0.0007	CcSEcCtD
Lurasidone—Nausea—Betamethasone—multiple sclerosis	0.000267	0.0007	CcSEcCtD
Lurasidone—Dizziness—Prednisone—multiple sclerosis	0.000259	0.000679	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—multiple sclerosis	0.000259	0.000678	CcSEcCtD
Lurasidone—Vomiting—Prednisone—multiple sclerosis	0.000249	0.000653	CcSEcCtD
Lurasidone—Rash—Prednisone—multiple sclerosis	0.000247	0.000648	CcSEcCtD
Lurasidone—Dermatitis—Prednisone—multiple sclerosis	0.000247	0.000647	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—multiple sclerosis	0.000235	0.000616	CcSEcCtD
Lurasidone—Nausea—Prednisone—multiple sclerosis	0.000233	0.00061	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—multiple sclerosis	0.000232	0.000607	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—multiple sclerosis	0.000224	0.000587	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—multiple sclerosis	0.000217	0.000568	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—multiple sclerosis	0.000208	0.000546	CcSEcCtD
Lurasidone—Rash—Methotrexate—multiple sclerosis	0.000207	0.000541	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—multiple sclerosis	0.000206	0.000541	CcSEcCtD
Lurasidone—Nausea—Methotrexate—multiple sclerosis	0.000195	0.00051	CcSEcCtD
Lurasidone—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	5.82e-05	0.000506	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	5.78e-05	0.000502	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	5.78e-05	0.000502	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	5.77e-05	0.000501	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCL10—multiple sclerosis	5.76e-05	0.0005	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCL5—multiple sclerosis	5.74e-05	0.000498	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CCR5—multiple sclerosis	5.69e-05	0.000495	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—IL6—multiple sclerosis	5.62e-05	0.000488	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—IL2RA—multiple sclerosis	5.61e-05	0.000487	CbGpPWpGaD
Lurasidone—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.59e-05	0.000486	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCL5—multiple sclerosis	5.55e-05	0.000482	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CCL5—multiple sclerosis	5.55e-05	0.000482	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CCR5—multiple sclerosis	5.51e-05	0.000479	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CCL5—multiple sclerosis	5.46e-05	0.000474	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—POMC—multiple sclerosis	5.45e-05	0.000474	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—IL2RA—multiple sclerosis	5.43e-05	0.000472	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—BCHE—multiple sclerosis	5.35e-05	0.000464	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CCL2—multiple sclerosis	5.34e-05	0.000463	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL10—multiple sclerosis	5.32e-05	0.000462	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	5.24e-05	0.000455	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL3—multiple sclerosis	5.24e-05	0.000455	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	5.24e-05	0.000455	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCR5—multiple sclerosis	5.17e-05	0.000449	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL2RA—multiple sclerosis	5.1e-05	0.000443	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL3—multiple sclerosis	5.07e-05	0.00044	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—ALB—multiple sclerosis	5.05e-05	0.000438	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTGER4—multiple sclerosis	5.05e-05	0.000438	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCL5—multiple sclerosis	5.04e-05	0.000438	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—IL2—multiple sclerosis	5.04e-05	0.000438	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCR5—multiple sclerosis	5e-05	0.000435	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CCR5—multiple sclerosis	5e-05	0.000434	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PGR—multiple sclerosis	4.97e-05	0.000432	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	4.97e-05	0.000431	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCL5—multiple sclerosis	4.96e-05	0.000431	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL2RA—multiple sclerosis	4.93e-05	0.000428	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—IL2RA—multiple sclerosis	4.93e-05	0.000428	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CCR5—multiple sclerosis	4.92e-05	0.000427	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTGER4—multiple sclerosis	4.88e-05	0.000424	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCR3—multiple sclerosis	4.87e-05	0.000423	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—IL2RA—multiple sclerosis	4.85e-05	0.000421	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—TYK2—multiple sclerosis	4.85e-05	0.000421	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CD28—multiple sclerosis	4.83e-05	0.000419	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PGR—multiple sclerosis	4.81e-05	0.000418	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCR2—multiple sclerosis	4.74e-05	0.000412	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCR3—multiple sclerosis	4.72e-05	0.00041	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CD28—multiple sclerosis	4.67e-05	0.000406	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CD86—multiple sclerosis	4.65e-05	0.000404	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL3—multiple sclerosis	4.6e-05	0.0004	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCR2—multiple sclerosis	4.59e-05	0.000398	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCL5—multiple sclerosis	4.58e-05	0.000397	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCR5—multiple sclerosis	4.54e-05	0.000394	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL3—multiple sclerosis	4.53e-05	0.000393	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	4.51e-05	0.000392	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	4.48e-05	0.000389	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL2RA—multiple sclerosis	4.47e-05	0.000389	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCR5—multiple sclerosis	4.47e-05	0.000388	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—POMC—multiple sclerosis	4.45e-05	0.000387	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—IL2—multiple sclerosis	4.44e-05	0.000386	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTGER4—multiple sclerosis	4.43e-05	0.000385	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	4.41e-05	0.000383	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL2RA—multiple sclerosis	4.4e-05	0.000382	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CNR1—multiple sclerosis	4.38e-05	0.00038	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PGR—multiple sclerosis	4.36e-05	0.000379	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTGER4—multiple sclerosis	4.36e-05	0.000379	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—BCHE—multiple sclerosis	4.34e-05	0.000377	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—POMC—multiple sclerosis	4.31e-05	0.000374	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PGR—multiple sclerosis	4.29e-05	0.000373	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCR3—multiple sclerosis	4.28e-05	0.000372	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.25e-05	0.000369	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.25e-05	0.000369	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CD28—multiple sclerosis	4.24e-05	0.000368	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SPP1—multiple sclerosis	4.24e-05	0.000368	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CNR1—multiple sclerosis	4.23e-05	0.000368	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCR3—multiple sclerosis	4.21e-05	0.000366	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CD28—multiple sclerosis	4.17e-05	0.000362	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCR2—multiple sclerosis	4.16e-05	0.000361	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCR5—multiple sclerosis	4.12e-05	0.000358	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	4.12e-05	0.000358	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	4.1e-05	0.000356	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—IL2—multiple sclerosis	4.09e-05	0.000355	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	4.06e-05	0.000353	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL2RA—multiple sclerosis	4.06e-05	0.000353	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—POMC—multiple sclerosis	4.04e-05	0.000351	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL2—multiple sclerosis	4.03e-05	0.00035	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	4.01e-05	0.000348	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	3.97e-05	0.000344	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCL2—multiple sclerosis	3.95e-05	0.000343	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL10—multiple sclerosis	3.94e-05	0.000342	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—TGFB1—multiple sclerosis	3.93e-05	0.000341	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—POMC—multiple sclerosis	3.91e-05	0.00034	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—POMC—multiple sclerosis	3.91e-05	0.000339	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	3.91e-05	0.000339	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.89e-05	0.000338	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—MAPK1—multiple sclerosis	3.85e-05	0.000335	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	3.85e-05	0.000334	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CNR1—multiple sclerosis	3.84e-05	0.000334	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	3.83e-05	0.000333	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCL2—multiple sclerosis	3.83e-05	0.000332	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL10—multiple sclerosis	3.81e-05	0.000331	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	3.79e-05	0.00033	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	3.78e-05	0.000328	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—APOE—multiple sclerosis	3.75e-05	0.000326	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	3.73e-05	0.000324	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—TYK2—multiple sclerosis	3.59e-05	0.000312	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—POMC—multiple sclerosis	3.55e-05	0.000308	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	3.5e-05	0.000304	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	3.49e-05	0.000303	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—TYK2—multiple sclerosis	3.47e-05	0.000302	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCL2—multiple sclerosis	3.47e-05	0.000302	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL10—multiple sclerosis	3.46e-05	0.0003	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CD86—multiple sclerosis	3.44e-05	0.000299	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	3.44e-05	0.000299	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	3.42e-05	0.000297	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	3.4e-05	0.000296	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CD80—multiple sclerosis	3.39e-05	0.000294	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL5—multiple sclerosis	3.39e-05	0.000294	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CD86—multiple sclerosis	3.33e-05	0.000289	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—IL2—multiple sclerosis	3.29e-05	0.000286	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL5—multiple sclerosis	3.28e-05	0.000285	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—POMC—multiple sclerosis	3.22e-05	0.00028	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.22e-05	0.00028	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—APOE—multiple sclerosis	3.22e-05	0.000279	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	3.19e-05	0.000277	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—IL2—multiple sclerosis	3.18e-05	0.000276	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	3.18e-05	0.000276	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	3.15e-05	0.000274	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCL2—multiple sclerosis	3.15e-05	0.000274	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SPP1—multiple sclerosis	3.14e-05	0.000273	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	3.13e-05	0.000272	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	3.11e-05	0.00027	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	3.1e-05	0.000269	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	3.1e-05	0.000269	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—MAPK1—multiple sclerosis	3.08e-05	0.000268	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	3.05e-05	0.000265	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SPP1—multiple sclerosis	3.04e-05	0.000264	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CD86—multiple sclerosis	3.02e-05	0.000263	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	3.01e-05	0.000261	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	2.99e-05	0.000259	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL5—multiple sclerosis	2.98e-05	0.000259	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CD86—multiple sclerosis	2.98e-05	0.000258	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	2.96e-05	0.000257	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	2.93e-05	0.000254	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	2.91e-05	0.000253	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	2.89e-05	0.000251	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	2.89e-05	0.000251	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TYK2—multiple sclerosis	2.86e-05	0.000249	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	2.84e-05	0.000247	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	2.82e-05	0.000245	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APOE—multiple sclerosis	2.78e-05	0.000241	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—POMC—multiple sclerosis	2.76e-05	0.00024	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SPP1—multiple sclerosis	2.76e-05	0.000239	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	2.71e-05	0.000236	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	2.71e-05	0.000235	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	2.69e-05	0.000234	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCR5—multiple sclerosis	2.68e-05	0.000233	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	2.67e-05	0.000231	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	2.64e-05	0.00023	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	2.64e-05	0.000229	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL2—multiple sclerosis	2.62e-05	0.000228	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—APOE—multiple sclerosis	2.61e-05	0.000227	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	2.6e-05	0.000226	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	2.59e-05	0.000225	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	2.58e-05	0.000224	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ALB—multiple sclerosis	2.52e-05	0.000219	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CD80—multiple sclerosis	2.51e-05	0.000218	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	2.47e-05	0.000214	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APOE—multiple sclerosis	2.44e-05	0.000212	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	2.43e-05	0.000211	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	2.4e-05	0.000209	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APOE—multiple sclerosis	2.4e-05	0.000209	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—POMC—multiple sclerosis	2.39e-05	0.000207	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL2—multiple sclerosis	2.38e-05	0.000207	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—multiple sclerosis	2.37e-05	0.000206	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	2.37e-05	0.000205	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	2.35e-05	0.000204	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	2.34e-05	0.000203	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	2.31e-05	0.000201	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	2.29e-05	0.000198	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	2.26e-05	0.000196	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—multiple sclerosis	2.25e-05	0.000196	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—POMC—multiple sclerosis	2.24e-05	0.000195	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	2.21e-05	0.000192	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CD80—multiple sclerosis	2.21e-05	0.000192	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	2.18e-05	0.00019	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CD80—multiple sclerosis	2.17e-05	0.000189	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	2.12e-05	0.000184	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—POMC—multiple sclerosis	2.1e-05	0.000182	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—POMC—multiple sclerosis	2.06e-05	0.000179	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	2.05e-05	0.000178	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL2—multiple sclerosis	2.05e-05	0.000178	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—multiple sclerosis	2.05e-05	0.000178	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	2.02e-05	0.000175	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	2.01e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—multiple sclerosis	2e-05	0.000174	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	1.97e-05	0.000172	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.97e-05	0.000171	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	1.88e-05	0.000163	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—multiple sclerosis	1.86e-05	0.000162	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TYK2—multiple sclerosis	1.86e-05	0.000162	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—multiple sclerosis	1.86e-05	0.000161	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.85e-05	0.000161	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	1.84e-05	0.000159	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	1.83e-05	0.000159	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK1—multiple sclerosis	1.82e-05	0.000158	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.8e-05	0.000156	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—multiple sclerosis	1.77e-05	0.000153	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	1.76e-05	0.000153	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	1.71e-05	0.000148	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	1.7e-05	0.000148	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	1.67e-05	0.000145	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	1.67e-05	0.000145	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	1.62e-05	0.00014	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—multiple sclerosis	1.55e-05	0.000135	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—multiple sclerosis	1.54e-05	0.000134	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—multiple sclerosis	1.52e-05	0.000132	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	1.52e-05	0.000132	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	1.49e-05	0.000129	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—multiple sclerosis	1.47e-05	0.000127	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	1.44e-05	0.000125	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	1.44e-05	0.000125	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—multiple sclerosis	1.4e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	1.39e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	1.38e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—multiple sclerosis	1.38e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	1.38e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	1.35e-05	0.000117	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	1.34e-05	0.000116	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	1.33e-05	0.000116	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	1.31e-05	0.000114	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	1.31e-05	0.000113	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—multiple sclerosis	1.3e-05	0.000113	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	1.28e-05	0.000111	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—multiple sclerosis	1.21e-05	0.000105	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	1.21e-05	0.000105	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—multiple sclerosis	1.19e-05	0.000104	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	1.19e-05	0.000103	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	1.19e-05	0.000103	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	1.17e-05	0.000101	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	1.17e-05	0.000101	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOE—multiple sclerosis	1.11e-05	9.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	1.08e-05	9.42e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	1.08e-05	9.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	1.06e-05	9.22e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—multiple sclerosis	1.04e-05	9.01e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	1e-05	8.72e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—POMC—multiple sclerosis	9.56e-06	8.3e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—multiple sclerosis	9.11e-06	7.91e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—multiple sclerosis	8.96e-06	7.78e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—multiple sclerosis	8.72e-06	7.57e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	8.15e-06	7.08e-05	CbGpPWpGaD
